Diroximel
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes.
Journal: Advances in therapy
Published: February 13, 2026
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Multiple sclerosis and related disorders
Published: December 12, 2025
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.
Journal: Advances in therapy
Published: October 23, 2025
Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.
Journal: International journal of molecular sciences
Published: October 16, 2025
Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.
Journal: Neurodegenerative disease management
Published: October 07, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Effect of diroximel fumarate on gut dysbiosis and autoimmunity in the central nervous system.
Journal: International immunopharmacology
Published: August 22, 2025
Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways.
Journal: Journal of neuroinflammation
Published: July 18, 2025
Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 22, 2025
Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 22, 2025
Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse events from the FDA adverse reporting system.
Journal: Expert opinion on drug safety
Published: April 02, 2025
Last Updated: 06/30/2026